NASDAQ · SGMT
Sagimet Biosciences Inc. Series A
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SGMT: Nov 12, 2026
Sagimet Biosciences Inc. Series A Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.25. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.25 | $-0.20 | $-0.28 | 4 |
| Dec 2026 | $-0.28 | $-0.22 | $-0.33 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews · BNK Invest- Zacks · Oct 23, 8:55 AM EDTWall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a BetThe consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Fintel · Oct 22, 11:12 AM EDTSagimet Biosciences Inc. Announces Clinical Updates for Denifanstat and TVB-3567Sagimet Biosciences Inc. announced clinical updates for its lead fatty acid synthase inhibitor, denifanstat, and its follow-on candidate, TVB-3567. In Oct 2026, the first patient was dosed in the AURORA Phase 3 clinical trial in the US for patients with moderate to severe acne, w
- RTTNews · Oct 22, 11:07 AM EDTSagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne Patients(RTTNews) – Sagimet Biosciences (SGMT) announced that the first patient has been dosed in AURORA, its pivotal U.S. Phase 3 clinical trial evaluating denifanstat for moderate to severe acne in adults and adolescents aged 12 years and older.
- BNK Invest · Oct 20, 12:25 PM EDTTuesday's ETF Movers: XBI, CRAKIn trading on Tuesday, the State Street SPDR S&P Biotech ETF is outperforming other ETFs, up about 3.5% on the day. Components of that ETF showing particular strength include shares of Myriad Genetics, up about 37.5% and shares of Sagimet Biosciences, up about 12.4% on the
- Zacks · Oct 15, 8:35 AM EDTAfter Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the
- BNK Invest · Oct 5, 3:27 PM EDTNotable Monday Option Activity: ONT, NET, SGMTLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Onterris Inc (Symbol: ONT), where a total volume of 5,437 contracts has been traded thus far today, a contract volume which is representative of approximately 54
- MarketBeat · Oct 3, 9:02 PM EDTSagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial LaunchSagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China. The company al
- RTTNews · Sep 30, 2:49 PM EDTBiotech Stocks Surge – NIVF +124%, CNTB +124%, SGMT +9%, VBIO +12%, AEON(RTTNews) – Several biotech and healthcare stocks moved sharply higher on September 30, 2026, following company-specific developments including clinical data, financing activity and regulatory updates.
- RTTNews · Sep 30, 7:48 AM EDTSagimet Prices $115 Mln Stock Offering, Pre-market Shares Up(RTTNews) – Sagimet Biosciences Inc. (SGMT), announced on Wednesday that it has priced an underwritten offering of 8.75 million shares of Series A common stock at $10 each, raising about $115 million.
- RTTNews · Sep 30, 7:17 AM EDTSagimet's Denifanstat Delivers Positive 52-Week Results In Acne Trial(RTTNews) – On Wednesday, Sagimet Biosciences Inc. (SGMT) reported positive 52-week results from its license partner Ascletis BioScience's Phase 3 open-label extension study of denifanstat in patients with moderate to severe acne vulgaris.
- RTTNews · Sep 30, 7:04 AM EDTSagimet Reports Positive 52-Week Data For Denifanstat In Acne(RTTNews) – Wednesday, Sagimet Biosciences (SGMT) reported positive 52-week results from a Phase 3 open-label extension study of denifanstat in patients with moderate to severe acne vulgaris, presented at EADV 2026.
- Fintel · Sep 9, 4:45 PM EDTCantor Fitzgerald Initiates Coverage of Sagimet Biosciences at OverweightFintel reports that on September 9, 2026, Cantor Fitzgerald initiated coverage of Sagimet Biosciences (NASDAQGM:SGMT) with a Overweight recommendation. On the same day, September 9, 2026, Barclays upgraded its rating on Sagimet Biosciences from Equal-Weight to Overweight. Prior t
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Sagimet Biosciences Inc. Series A from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.